Effects of vitamin D on prostate cancer: Prof Reinhold Vieth - University of Toronto, Ontario, Canada

Cancer in the developing world: Dr Tim Rebbeck - University of Pennsylvania, Philadelphia, USA

Metformin's effect on breast cancer: Dr Vuk Stambolic - Ontario Cancer Institute, Toronto, Canada

Noninvasive imaging markers in prostate cancer: Dr Michael Evans - Memorial Sloan-Kettering Cancer Center, New York, USA

EGFR mutation unique to glioblastoma linked to lack of response: Dr Ingo Mellinghoff - Memorial Sloan-Kettering Cancer Center

Biomarker identified in relation to pazopanib in urothelial cancer: Dr Andrea Necchi - National Cancer Institute of Milan

Anti-angiogenic agents and cancer stem cells: Dr Max Wicha - University of Michigan, Ann Arbor, USA

Non invasive biomarkers for prostate cancer

Hypoxia influenced tumour behaviour in prostate cancer: Dr Michael Milosevic - University of Toronto, Ontario, Canada

Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

Selumetinib controlled recurrent low-grade serous ovarian cancer: Dr John Farley - Creighton University, Phoenix, Arizona, USA

Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center

Metformin to slow prostate cancer growth: Dr Anthony Joshua - Princess Margaret Hospital, Toronto, Canada

Targeting the cancer genome: Dr Bill Sellers - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

Effects of metformin in pancreatic cancer with diabetes: Prof Donghui Li - University of Texas MD Anderson Cancer Center

Nutrition and supplements for cancer survivors: Prof Susan Mayne - Yale University, Connecticut, USA